Ignite Creation Date:
2024-05-06 @ 5:07 PM
Last Modification Date:
2024-10-26 @ 2:23 PM
Study NCT ID:
NCT05207722
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2023-02-16
First Post:
2022-01-12
Brief Title:
CYNK-101 in Combination With Trastuzumab and Pembrolizumab in Patients With Locally Advanced Unresectable or Metastatic HER2-Positive Gastric or Gastroesophageal Junction GGEJ Adenocarcinoma
Sponsor:
Celularity Incorporated
Organization:
Celularity Incorporated
Organization Data
Organization:
Celularity Incorporated
Class:
INDUSTRY
Study ID:
CYNK-101-HER2-001
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Celularity Incorporated
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None